Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
New Journal of Chemistry ; 2023.
Article in English | Web of Science | ID: covidwho-20235486

ABSTRACT

Based on signal amplification strategy of dendritic mesoporous silica nanospheres loaded with CdSe/ZnS quantum dots (DMSN@QDs), an ultrasensitive electrochemiluminescence (ECL) immunosensor with magnetic separation was constructed for the detection of SARS-CoV-2 nucleocapsid protein (NP). DMSN, a mesoporous material with abundant radial pores, large specific surface area and high porosity, can increase the loading capacity of QDs and hinder their aggregation as the nanocarrier. DMSN@QDs with good ECL efficiency were used as signal labels to construct a sandwich immunosensor. The designed ECL immunosensor displayed a good linear relationship for NP concentrations ranging from 0.005 ng mL(-1) to 50 ng mL(-1), with a limit of detection of 3.33 pg mL(-1). The ECL immunosensor was successfully applied to detect NP in human serum samples with satisfactory recovery. This strategy provided a new method for detecting NP and expanded the application field of DMSN.

2.
Chinese Journal of Clinical Infectious Diseases ; 13(1):9-15, 2020.
Article in Chinese | EMBASE | ID: covidwho-2305597

ABSTRACT

Objective: To compare the efficacy of the combination of abidol, lopinavir/ritonavir plus recombinant interferon alpha-2b (rIFNalpha-2b) and the combination of lopinavir/ritonavir plus rIFNalpha-2b for patients with COVID-19 in Zhejiang province. Method(s): A multicenter prospective study was carried out to compare the efficacy of triple combination antiviral therapy and dual combination antiviral therapy in 15 medical institutions of Zhejiang province during January 22 to February 16, 2020. All patients were treated with rIFNalpha-2b (5 million U, 2 times/d) aerosol inhalation, in addition 196 patients were treated with abidol (200 mg, 3 times/d) + lopinavir/ritonavir (2 tablets, 1 time/12 h) (triple combination group) and 41 patients were treated with lopinavir/ritonavir (2 tablets, 1 time/12 h) (dual combination group). The patients who received triple combination antiviral therapy were further divided into three subgroups: <48 h, 3-5 d and >5 d according the time from the symptom onset to medication starting. The therapeutic efficacy was compared between triple combination group and dual combination group, and compared among 3 subgroups of patients receiving triple combination antiviral therapy. SPSS 17.0 software was used to analyze the data. Result(s): The virus nucleic acid-negative conversion time in respiratory tract specimens was (12.2+/-4.7) d in the triple combination group, which was shorter than that in the dual combination group [(15.0+/-5.0) d] (t=6.159, P<0.01). The length of hospital stay in the triple combination group [12.0 (9.0, 17.0) d] was also shorter than that in the dual combination group [15.0 (10.0, 18.0) d] (H=2.073, P<0.05). Compared with the antiviral treatment which was started within after the symptom onset of in the triple combination group, the time from the symptom onset to the viral negative conversion was 13.0 (10.0, 17.0), 17.0 (13.0, 22.0) and 21.0 (18.0, 24.0) d in subgroups of 48 h, 3-5 d and >5 d, respectively (Z=32.983, P<0.01), while the time from antiviral therapy to viral negative conversion was (11.8+/-3.9), (13.5+/-5.1) and (11.2+/-4.3) d, respectively(Z=6.722, P<0.05). Conclusion(s): The triple combination antiviral therapy of abidol, lopinavir/litonavir and rIFNalpha-2b shows shorter viral shedding time and shorter hospitalization time, compared with the dual combination antiviral therapy;and the earlier starting triple combination antiviral therapy will result in better antiviral efficacy.Copyright © 2020 by the Chinese Medical Association.

3.
Adverse Drug Reactions Journal ; 23(7):352-356, 2021.
Article in Chinese | EMBASE | ID: covidwho-2304847

ABSTRACT

Patients with cancer are at high risk for coronavirus disease 2019 (COVID-19). Institutions for disease control and prevention and cancer-related learned societies in many countries recommend prioritizing cancer patients for COVID-19 vaccines. All the COVID-19 vaccines currently approved for emergency use, including inactivated vaccines, mRNA vaccines, recombinant adenovirus vector-based vaccines, and recombinant protein subunit vaccines, can be applied in cancer patients. Cancer patients with stable disease can be vaccinated against COVID-19 at any time, while patients with advanced-stage cancer or undergoing anticancer therapy should decide on the timing of vaccination according to the specific situation such as treatment methods and cancer type, etc.. The benefits of COVID-19 vaccination in cancer patients may outweigh the risks, but the immune response rate may be lower in cancer patients, especially in patients with haematological malignancies, than in healthy individuals.Copyright © 2021 by the Chinese Medical Association.

4.
Medical Journal of Chinese People's Liberation Army ; 47(11):1085-1091, 2022.
Article in Chinese | EMBASE | ID: covidwho-2268775

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic is a serious threat to human life, health and social development. In response to this public health event, various COVID-19 vaccines have been rapidly developed around the world. To date, 41 vaccines have been approved for emergency use, and the use of vaccines has significantly reduced the morbidity and mortality of COVID-19. However, with the continuous mutants, especially the emergence of the Omicron variant, challenges to vaccine-induced immune protection are appearing, there is still a long way to go for the continued development of COVID-19 vaccines. This article briefly reviews the research progress of COVID-19 vaccine and its effect on mutant virus strains.Copyright © 2022 Authors. All rights reserved.

5.
Medical Journal of Chinese People's Liberation Army ; 47(11):1079-1084, 2022.
Article in Chinese | EMBASE | ID: covidwho-2288503

ABSTRACT

Objective To analyze the potential factors influencing the viral shedding time (duration of nucleic acid positivity) in elderly patients with mild and asymptomatic infection. Methods The clinical data of 1141 elderly (>=60 years) patients with mild and asymptomatic Omicron infection who were admitted to National Exhibition and Convention Center (Shanghai) Cabin Hospital from April 14, 2022 to May 1, 2022 were retrospectively collected, viral shedding time of patients were compared between different groups (age, gender, number of vaccination, hypertension, diabetes). Pearson analysis was adopted to analyze the relationship between age and viral shedding time. Kaplan-Meier curve and Log-rank test were used to evaluate the viral shedding time in elderly patients with different clinical characteristics. Multivariate Cox proportional-hazards regression model was adopted to analyze the factors influencing viral shedding time in elderly patients with Omicron. Results Among 1441 patients, 791(54.9%) males and 650(45.1%) females. There were 513(35.6%) patients receiving 0 dose of vaccine, 29(2.0%) patients received 1 dose of vaccine, 405(28.1%) patients received 2 doses of vaccine, 494(34.3%) patients received 3 doses of vaccine. Compared with patients aged 60 to 70 years, patients aged 70 to 80 years had longer viral shedding time (P<0.001). The viral shedding time in patients with hypertension and diabetes was longer than that in patients without hypertension and diabetes (P<0.05). In terms of vaccination, the viral shedding time of patients receiving 2 or 3 doses of vaccine was significantly shorter than that of patients receiving 1 dose of vaccine or none (P<0.05). There was a positive correlation between patient age and viral shedding time, with an R2=0.029 (P<0.001). Kaplan-Meier curve showed that there existed significant difference in viral shedding time between the patients with different vaccination doses (P<0.001), and patients with age >=70, hypertension and diabetes were all associated with prolonged viral shedding time (P<0.05). Cox regression analysis showed that the age >=70 years was a risk factor for prolonged viral shedding time, and 2 or 3 doses of vaccine was a protective factor for prolonged viral shedding time (P<0.05). Conclusions Among the elderly population, the viral shedding time would gradually increase with age. Patients who received >=2 doses of vaccine would have reduced viral shedding time compared with those who received <2 doses of vaccine.Copyright © 2022 Authors. All rights reserved.

6.
Chinese Journal of Clinical Infectious Diseases ; 13(1):9-15, 2020.
Article in Chinese | EMBASE | ID: covidwho-2286480

ABSTRACT

Objective: To compare the efficacy of the combination of abidol, lopinavir/ritonavir plus recombinant interferon alpha-2b (rIFNalpha-2b) and the combination of lopinavir/ritonavir plus rIFNalpha-2b for patients with COVID-19 in Zhejiang province. Method(s): A multicenter prospective study was carried out to compare the efficacy of triple combination antiviral therapy and dual combination antiviral therapy in 15 medical institutions of Zhejiang province during January 22 to February 16, 2020. All patients were treated with rIFNalpha-2b (5 million U, 2 times/d) aerosol inhalation, in addition 196 patients were treated with abidol (200 mg, 3 times/d) + lopinavir/ritonavir (2 tablets, 1 time/12 h) (triple combination group) and 41 patients were treated with lopinavir/ritonavir (2 tablets, 1 time/12 h) (dual combination group). The patients who received triple combination antiviral therapy were further divided into three subgroups: <48 h, 3-5 d and >5 d according the time from the symptom onset to medication starting. The therapeutic efficacy was compared between triple combination group and dual combination group, and compared among 3 subgroups of patients receiving triple combination antiviral therapy. SPSS 17.0 software was used to analyze the data. Result(s): The virus nucleic acid-negative conversion time in respiratory tract specimens was (12.2+/-4.7) d in the triple combination group, which was shorter than that in the dual combination group [(15.0+/-5.0) d] (t=6.159, P<0.01). The length of hospital stay in the triple combination group [12.0 (9.0, 17.0) d] was also shorter than that in the dual combination group [15.0 (10.0, 18.0) d] (H=2.073, P<0.05). Compared with the antiviral treatment which was started within after the symptom onset of in the triple combination group, the time from the symptom onset to the viral negative conversion was 13.0 (10.0, 17.0), 17.0 (13.0, 22.0) and 21.0 (18.0, 24.0) d in subgroups of 48 h, 3-5 d and >5 d, respectively (Z=32.983, P<0.01), while the time from antiviral therapy to viral negative conversion was (11.8+/-3.9), (13.5+/-5.1) and (11.2+/-4.3) d, respectively(Z=6.722, P<0.05). Conclusion(s): The triple combination antiviral therapy of abidol, lopinavir/litonavir and rIFNalpha-2b shows shorter viral shedding time and shorter hospitalization time, compared with the dual combination antiviral therapy;and the earlier starting triple combination antiviral therapy will result in better antiviral efficacy.Copyright © 2020 by the Chinese Medical Association.

7.
Medical Journal of Chinese People's Liberation Army ; 47(11):1079-1084, 2022.
Article in Chinese | EMBASE | ID: covidwho-2203677

ABSTRACT

Objective To analyze the potential factors influencing the viral shedding time (duration of nucleic acid positivity) in elderly patients with mild and asymptomatic infection. Methods The clinical data of 1141 elderly (>=60 years) patients with mild and asymptomatic Omicron infection who were admitted to National Exhibition and Convention Center (Shanghai) Cabin Hospital from April 14, 2022 to May 1, 2022 were retrospectively collected, viral shedding time of patients were compared between different groups (age, gender, number of vaccination, hypertension, diabetes). Pearson analysis was adopted to analyze the relationship between age and viral shedding time. Kaplan-Meier curve and Log-rank test were used to evaluate the viral shedding time in elderly patients with different clinical characteristics. Multivariate Cox proportional-hazards regression model was adopted to analyze the factors influencing viral shedding time in elderly patients with Omicron. Results Among 1441 patients, 791(54.9%) males and 650(45.1%) females. There were 513(35.6%) patients receiving 0 dose of vaccine, 29(2.0%) patients received 1 dose of vaccine, 405(28.1%) patients received 2 doses of vaccine, 494(34.3%) patients received 3 doses of vaccine. Compared with patients aged 60 to 70 years, patients aged 70 to 80 years had longer viral shedding time (P<0.001). The viral shedding time in patients with hypertension and diabetes was longer than that in patients without hypertension and diabetes (P<0.05). In terms of vaccination, the viral shedding time of patients receiving 2 or 3 doses of vaccine was significantly shorter than that of patients receiving 1 dose of vaccine or none (P<0.05). There was a positive correlation between patient age and viral shedding time, with an R2=0.029 (P<0.001). Kaplan-Meier curve showed that there existed significant difference in viral shedding time between the patients with different vaccination doses (P<0.001), and patients with age >=70, hypertension and diabetes were all associated with prolonged viral shedding time (P<0.05). Cox regression analysis showed that the age >=70 years was a risk factor for prolonged viral shedding time, and 2 or 3 doses of vaccine was a protective factor for prolonged viral shedding time (P<0.05). Conclusions Among the elderly population, the viral shedding time would gradually increase with age. Patients who received >=2 doses of vaccine would have reduced viral shedding time compared with those who received <2 doses of vaccine. Copyright © 2022 Authors. All rights reserved.

8.
Chinese General Practice ; 25(30):3726-3733, 2022.
Article in Chinese | Scopus | ID: covidwho-2145253

ABSTRACT

Background The transmission speed and concealment of the Omicron variant of SARS-CoV-2 have been enhanced. The awareness level and skills of correctly donning and doffing personal protective equipment (PPE) in SARS-CoV-2 containment workers from the mobile cabin hospital are associated with their own health status, and the overall quality of COVID-19 pandemic control. Objective To understand the awareness and skills of correctly donning and doffing PPE in SARS-CoV-2 containment workers from a mobile cabin hospital. Methods By use of cluster sampling, 460 SARS-CoV-2 containment workers were selected from the Fourth Branch of Shanghai Mobile Cabin Hospital located in the National Exhibition and Convention Center (Shanghai), from April 10 to May 10, 2022. Their awareness and skills of correctly donning and doffing PPE were assessed using an online survey with a self-developed questionnaire named Awareness of Correctly Donning and Doffing Personal Protective Equipment, and using an onsite performance assessment with a self-developed questionnaire named Skills of Correctly Donning and Doffing Personal Protective Equipment, respectively. Results The survey obtained a response rate of 83.5% (384/460). According to the survey, both doctors and nurses had significantly higher average scores with regards to the operations at the first donning area, second donning area, front doffing area and first doffing area, second doffing area, and hand hygiene disinfection than public security officers and fire fighters(P<0.05). All of the 460 cases completed the onsite performance assessment. Both doctors and nurses obtained lower average scores in terms of completing the operations at the first donning area, and donning steps in clean area into contaminated area than public security officers and fire fighters (P<0.05). Doctors had much lower average score for completing the operations at the first donning area than nurses (P<0.05). Conclusion There were significant differences in the levels of awareness and skills of correctly donning and doffing PPE in SARS-CoV-2 containment workers by occupation. Targeted and focused trainings and supervisions should be carried out to improve the mismatching between the levels of awareness and skills. © 2022 Chinese General Practice. All rights reserved.

9.
35th IEEE International Conference on Micro Electro Mechanical Systems Conference (IEEE MEMS) ; : 365-368, 2022.
Article in English | Web of Science | ID: covidwho-1822038

ABSTRACT

This study presents a facile route to fabricate a novel kind of digital microfluidic (DMF) chip via direct ink writing. The manufacture of this device does not rely on conventional microfabrication processes and cleanrooms, which makes it easy to prepare and low cost. By measuring the change of contact angle (CA) and droplet velocity, we proved that it could perform droplet manipulation like traditional DMF chips. In addition, after optimizing the chip structure, through a peripheral support circuit, polymerase chain reaction (PCR) reagents could be automatically partitioned and mixed on the chip. Furthermore, we realized the multi-target end-point fluorescence detection of SARS-CoV-2 RNA on this chip, showing promising potential for automatic nucleic acid tests.

10.
Micro & Nano Letters ; : 10, 2022.
Article in English | Web of Science | ID: covidwho-1612222

ABSTRACT

With the rapid spread and proliferation of Coronavirus disease 2019 (COVID-19) worldwide, highly pathogenic severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) seriously threatens human life and health. The rapid and accurate abilities to detect SARS-CoV-2 have become the key to prevent and control COVID-19. Electrochemical sensors have shown broad application prospects in biological detection because of the advantages of high sensitivity, specificity, and short time-consuming. This review summarizes the application of electrochemical biosensors in detecting SARS-CoV-2 and discusses prospects for developing direction in this field.

12.
Adverse Drug Reactions Journal ; 23(7):352-356, 2021.
Article in Chinese | Scopus | ID: covidwho-1362630

ABSTRACT

Patients with cancer are at high risk for coronavirus disease 2019 (COVID-19). Institutions for disease control and prevention and cancer-related learned societies in many countries recommend prioritizing cancer patients for COVID-19 vaccines. All the COVID-19 vaccines currently approved for emergency use, including inactivated vaccines, mRNA vaccines, recombinant adenovirus vector-based vaccines, and recombinant protein subunit vaccines, can be applied in cancer patients. Cancer patients with stable disease can be vaccinated against COVID-19 at any time, while patients with advanced-stage cancer or undergoing anticancer therapy should decide on the timing of vaccination according to the specific situation such as treatment methods and cancer type, etc.. The benefits of COVID-19 vaccination in cancer patients may outweigh the risks, but the immune response rate may be lower in cancer patients, especially in patients with haematological malignancies, than in healthy individuals. Copyright © 2021 by the Chinese Medical Association.

13.
2021 International Conference on Economic Innovation and Low-carbon Development, EILCD 2021 ; 275, 2021.
Article in English | Scopus | ID: covidwho-1284723

ABSTRACT

Agriculture is a basic industry that supports the construction and development of the national economy and plays an important role in promoting rural revitalization. And in the current post-COVID-19 era, agricultural SMEs have difficulty in obtaining the favours of financial institutions in normal lending due to their weak credit guarantee capabilities and high credit management costs. Difficulty in financing has become a bottleneck problem that plagues the development of enterprises and restricts the development of agricultural modernization. How to evaluate and control its credit risk is not only a major way to solve the financing difficulties of agricultural SMEs, but also the basis for the stable development of supply chain financial services. This paper analyzes three typical financing modes of agricultural SMEs from the perspective of supply chain finance, and takes the agricultural SMEs in the New OTC Market as an example to construct a Logistic model, and uses factor analysis to effectively predict the credit risk of supply chain finance. The results show that the operational efficiency factors, growth factors and related core corporate profitability of agricultural SMEs financing enterprises significantly affect their credit risk. After testing, the model is highly accurate in predicting the financing risks of agricultural SMEs. © The Authors, published by EDP Sciences, 2021.

14.
Chinese Journal of Clinical Infectious Diseases ; 13(1):9-15, 2020.
Article in Chinese | Scopus | ID: covidwho-1143641

ABSTRACT

Objective: To compare the efficacy of the combination of abidol, lopinavir/ritonavir plus recombinant interferon α-2b (rIFNα-2b) and the combination of lopinavir/ritonavir plus rIFNα-2b for patients with COVID-19 in Zhejiang province. Methods: A multicenter prospective study was carried out to compare the efficacy of triple combination antiviral therapy and dual combination antiviral therapy in 15 medical institutions of Zhejiang province during January 22 to February 16, 2020. All patients were treated with rIFNα-2b (5 million U, 2 times/d) aerosol inhalation, in addition 196 patients were treated with abidol (200 mg, 3 times/d) + lopinavir/ritonavir (2 tablets, 1 time/12 h) (triple combination group) and 41 patients were treated with lopinavir/ritonavir (2 tablets, 1 time/12 h) (dual combination group). The patients who received triple combination antiviral therapy were further divided into three subgroups: <48 h, 3-5 d and >5 d according the time from the symptom onset to medication starting. The therapeutic efficacy was compared between triple combination group and dual combination group, and compared among 3 subgroups of patients receiving triple combination antiviral therapy. SPSS 17.0 software was used to analyze the data. Results: The virus nucleic acid-negative conversion time in respiratory tract specimens was (12.2±4.7) d in the triple combination group, which was shorter than that in the dual combination group [(15.0±5.0) d] (t=6.159, P<0.01). The length of hospital stay in the triple combination group [12.0 (9.0, 17.0) d] was also shorter than that in the dual combination group [15.0 (10.0, 18.0) d] (H=2.073, P<0.05). Compared with the antiviral treatment which was started within after the symptom onset of in the triple combination group, the time from the symptom onset to the viral negative conversion was 13.0 (10.0, 17.0), 17.0 (13.0, 22.0) and 21.0 (18.0, 24.0) d in subgroups of 48 h, 3-5 d and >5 d, respectively (Z=32.983, P<0.01), while the time from antiviral therapy to viral negative conversion was (11.8±3.9), (13.5±5.1) and (11.2±4.3) d, respectively(Z=6.722, P<0.05). Conclusions: The triple combination antiviral therapy of abidol, lopinavir/litonavir and rIFNα-2b shows shorter viral shedding time and shorter hospitalization time, compared with the dual combination antiviral therapy;and the earlier starting triple combination antiviral therapy will result in better antiviral efficacy. Copyright © 2020 by the Chinese Medical Association.

16.
Zhonghua Jie He He Hu Xi Za Zhi ; 43(9): 728-732, 2020 Sep 12.
Article in Chinese | MEDLINE | ID: covidwho-749116

ABSTRACT

The novel coronavirus pneumonia (COVID-19) has been well controlled in China. Most of the COVID-19 patients were having postinflammatory pulmonary fibrosis (PPF) on the follow-up CT scan when discharged, and complaining about exertional dyspnea of different levels, presenting with an UIP (usual interstitial pneumonia) pattern or NSIP (non-specific interstitial pneumonia) pattern on the CT scans. Will the PPF get improved or stay stable, or progress? Such questions could only be answered by follow-up and monitoring of the pulmonary function. At the same time, we should learn from the lessons on pulmonary function loss of the SARS patients and MERS patients, some of whom had persistent impaired lung function after discharge. Pirfenidone and Nintedanib had been approved for the treatment of idiopathic pulmonary fibrosis(IPF), showing effectiveness on non-IPF pulmonary fibrosis as well. However, there are no studies about the application on PPF resulting from viral pneumonia. Given the follow-up status of SARS patients and MERS patients, and the PPF of COVID-19 patients, we should be careful about the discharged patients with a close follow-up, and further studies on PPF of COVID-19 are needed.


Subject(s)
Betacoronavirus , Coronavirus Infections , Idiopathic Pulmonary Fibrosis , Pandemics , Pneumonia, Viral , COVID-19 , Humans , Lung , SARS-CoV-2
18.
Zhonghua Jie He He Hu Xi Za Zhi ; 43(4): 273-277, 2020 Apr 12.
Article in Chinese | MEDLINE | ID: covidwho-590278

ABSTRACT

COVID-19 has been prevalent in Wuhan and spread rapidly to all of our country. Some cases can develop into ARDS, or even death. We will share the treatment experience of severe COVID-19 with the first-line treatment experience. The best respiratory support mode should be selected, but the timing of intubation and protection during intubation are two difficulties; patients with high level peep and poor effect in prone position can be given ECMO support. For COVID-19 patients with mechanical ventilation, reasonable sedation and analgesia strategies should be formulated; delirium should not be ignored. In addition, there is up regulation of inflammatory factors in patients with severe COVID-19, but the effect of renal replacement therapy needs to be further confirmed by clinical research.


Subject(s)
Coronavirus Infections/therapy , Pneumonia, Viral/therapy , Analgesia , Betacoronavirus , COVID-19 , Conscious Sedation , Delirium , Humans , Inflammation , Intubation , Pandemics , Renal Replacement Therapy , Respiration, Artificial , SARS-CoV-2
19.
Zhonghua Jie He He Hu Xi Za Zhi ; 43(4): 277-281, 2020 Apr 12.
Article in Chinese | MEDLINE | ID: covidwho-2875

ABSTRACT

The treatment of critically ill patients with coronavirus disease 2019(COVID-19) faces compelling challenges. In this issue, we'd like to share our first-line treatment experience in treating COVID-19. Hemodynamics need be closely monitored and different types of shock should be distinguished. Vasoconstrictor drugs should be used rationally and alerting of complications is of the same importance. The risk of venous thromboembolism (VTE) needs to be assessed, and effective prevention should be carried out for high-risk patients. It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure. However, comprehensive analysis of disease state should be taken into the interpretation of abnormally elevated D-Dimer. Nutritional support is the basis of treatment. It's important to establish individual therapy regimens and to evaluate, monitor and adjust dynamically. Under the current epidemic situation, convalescent plasma can only be used empirically, indications need to be strictly screened, the blood transfusion process should be closely monitored and the curative effect should be dynamically evaluated.


Subject(s)
Coronavirus Infections/complications , Coronavirus Infections/therapy , Pneumonia, Viral/complications , Pneumonia, Viral/therapy , Betacoronavirus , Blood Transfusion , COVID-19 , Coronavirus Infections/drug therapy , Critical Illness , Fibrin Fibrinogen Degradation Products/analysis , Hemodynamics , Humans , Nutritional Support , Pandemics , Pulmonary Embolism/diagnosis , Pulmonary Embolism/prevention & control , SARS-CoV-2 , Shock/diagnosis , Shock/therapy , Vasoconstrictor Agents/therapeutic use , Venous Thromboembolism/diagnosis , Venous Thromboembolism/prevention & control , COVID-19 Drug Treatment
20.
Zhonghua Jie He He Hu Xi Za Zhi ; 43(0): E012, 2020 Feb 14.
Article in Chinese | MEDLINE | ID: covidwho-1150

ABSTRACT

The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-α is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.

SELECTION OF CITATIONS
SEARCH DETAIL